Susan Iannaccone
Neurology · Dallas, TXNPI 1023078607
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Novartis Gene Therapies, Inc. (fka Avexis, Inc.) at 54.7% of the total. Reporting peaked in 2019 at $32,194 and has fallen 93.0% since, to $2,260 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $370.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$46K
- Biogen$16K
- Sarepta Therapeutics, Inc.$11K
- Genentech USA, Inc.$9K
- Merck$2K
- UCB, Inc.$269
- plus $280 from 5 others
Across 438 payments — averaging $11,546 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$2.3M
- Biogen$2.1M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$226K
- PTC Therapeutics, Inc.$189K
- Novartis$90K
- Mallinckrodt Enterprises LLC$65K
- plus $60K from 3 others
What the payments were for
- Consulting fees$28,58334%
- Speaking & faculty fees$13,73416%
- Travel & lodging$2,5823%
- Food & beverage$2,7913%
- Education$36,50143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 165 | $46,072 |
| Biogen | 15 | $15,867 |
| Sarepta Therapeutics, Inc. | 13 | $10,604 |
| Genentech USA, Inc. | 18 | $9,039 |
| Merck | 1 | $2,060 |
| UCB, Inc. | 3 | $269 |
| PTC Therapeutics, Inc. | 3 | $101 |
| NS Pharma, Inc. | 4 | $67 |
| Sanofi | 2 | $51 |
| Genentech, Inc. | 2 | $44 |
| Immedica Pharma US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOLGENSMA$45,258
- Non-Covered Product$8,811
- SPINRAZA$8,086
- Elevidys$4,839
- Skyclarys$1,500
How this compares
$84,191 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.